In ovarian cancer models, co-treatment with BMX-001 and PTX significantly reduced the cell viability of CAOV2 cells compared to PTX alone and downregulated the expression of BCL2, NF-κB, and IL-1β [49]. Here, BCL2 is linked to ovarian carcinoma.